恩诺单抗维多汀在晚期尿路上皮癌及其他恶性实体瘤中的临床药理学
本综述总结了恩诺单抗维多汀单药的临床药理学,基于5项临床试验(n=748)的PK数据,涵盖抗体偶联药物、总抗体和游离MMAE。结果显示0.5-1.25 mg/kg剂量范围内PK呈线性,支持1.25 mg/kg单药用于晚期尿路上皮癌;肾功能不全或轻度肝损伤无需调整剂量。
要点
- 恩诺单抗维多汀0.5-1.25 mg/kg呈线性、剂量比例PK。
- 轻中重度肾损伤无需调整剂量,轻度肝损伤也无需调整。
- 与双P-gp和强CYP3A4抑制剂合用可能增加MMAE暴露和不良事件风险。
核心结论
- 恩诺单抗维多汀1.25 mg/kg单药(28天周期第1、8、15天)的剂量选择得到临床药理学支持。
研究设计与样本
- 综述总结了恩诺单抗维多汀单药的临床药理学,PK数据来自5项临床试验的748例局部晚期或转移性尿路上皮癌患者。
主要发现
- 恩诺单抗维多汀0.5-1.25 mg/kg静脉给药呈线性、剂量比例PK。
- 轻、中、重度肾损伤与正常肾功能相比,恩诺单抗维多汀和游离MMAE的暴露或安全性无显著差异。
- 轻度肝损伤与正常肝功能相比,游离MMAE的AUC(0-28天)增加37%、Cmax增加31%,不良事件特征相似。
- 按体重给药时,种族/民族间未观察到有临床意义的PK差异,也未观察到有临床意义的QT间期延长。
- 约3%的患者在1.25 mg/kg剂量下产生抗恩诺单抗维多汀抗体。
关键数值与推荐
- 恩诺单抗维多汀推荐剂量为1.25 mg/kg,28天周期第1、8、15天静脉给药。
- 肾损伤或轻度肝损伤患者无需调整剂量。
- 按体重给药时无需根据种族/民族调整剂量。
- 与双P-gp和强CYP3A4抑制剂合用可能增加MMAE暴露和不良事件风险。
临床怎么用
- 临床可按1.25 mg/kg(28天周期第1、8、15天)使用恩诺单抗维多汀单药治疗。
- 肾损伤或轻度肝损伤患者及不同种族/民族患者按体重给药时无需调整剂量。
- 合并使用双P-gp和强CYP3A4抑制剂时应警惕MMAE暴露增加及不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enfortumab vedotin is an antibody-drug conjugate comprised of a human monoclonal antibody directed to Nectin-4 and monomethyl auristatin E (MMAE), a microtubule-disrupting agent. The objectives of this review are to summarize the clinical pharmacology of enfortumab vedotin monotherapy and demonstrate that the appropriate dose has been selected for clinical use. Pharmacokinetics (PK) of enfortumab vedotin (antibody-drug conjugate and total antibody) and free MMAE were evaluated in five clinical trials of patients with locally advanced or metastatic urothelial carcinoma (n = 748). Intravenous enfortumab vedotin 0.5-1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle showed linear, dose-proportional PK. No significant differences in exposure or safety of enfortumab vedotin and free MMAE were observed in mild, moderate, or severe renal impairment versus normal renal function. Patients with mildly impaired versus normal hepatic function had a 37% increase in area under the concentration-time curve (0-28 days), a 31% increase in maximum concentration of free MMAE, and a similar adverse event profile. No clinically significant PK differences were observed based on race/ethnicity with weight-based dosing, and no clinically meaningful QT prolongation was observed. Concomitant use with dual P-glycoprotein and strong cytochrome P450 3A4 inhibitors may increase MMAE exposure and the risk of adverse events. Approximately 3% of patients developed antitherapeutic antibodies against enfortumab vedotin 1.25 mg/kg. These findings support enfortumab vedotin 1.25 mg/kg monotherapy on days 1, 8, and 15 of a 28-day cycle. No dose adjustments are required for patients with renal impairment or mild hepatic impairment, or by race/ethnicity.
引用
- Tang M, Garg A, Bonate PL, et al. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Clin Pharmacokinet. 2024. PMID: 38609704. doi:10.1007/s40262-024-01369-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。